News

Lifitegrast shows rapid and sustained relief for dry eye disease, with high satisfaction among providers and patients, according to recent findings.

Younger age and recurrent disease significantly increase the risk of pterygium progression, highlighting critical factors for ophthalmologists.

A study reveals Johnson & Johnson’s TECNIS Odyssey IOL offers excellent vision for presbyopia, with minimal dysphotopsia bothersomeness reported by patients.

BRIMOCHOL PF offers lasting near vision improvement for presbyopia, demonstrating robust efficacy and safety in a landmark Phase 3 study.

Travoprost intracameral implant significantly reduces intraocular pressure and medication use in patients with glaucoma over three years.

A Phase 1/2 trial shows promising results for corneal edema, highlighting significant visual and quality of life improvements with an innovative cell therapy.

Long-term analysis confirms lifitegrast's safety for dry eye treatment, showing no new safety signals in nearly 800,000 patient treatment years.

Cyclosporine 0.09% significantly improves dry eye symptoms in patients inadequately treated with lower concentrations, enhancing quality of life.

Gene therapy could revolutionize retinal disease treatment, promising consistent dosing, fewer injections, and improved patient outcomes, as highlighted by expert Christina Y. Weng.

Innovative drug delivery platform shows significant vision improvement and IOP reduction in glaucoma patients, promising a new treatment paradigm.

Jeffrey Levenson, MD, discusses the sustained reduction of ocular inflammation and pain post ocular surgery with clobetasol propionate ophthalmic suspension.

Katherine Talcott, MD, discuss the impact of intravitreal injections on intraocular pressure, emphasizing monitoring and patient safety in treatment.

Young shared with his real-world experiences with etranacogene dezaparvovec gene therapy.

Christina Y. Weng, MD, breaks down emerging gene therapy programs poised to change how retina specialists treat chronic eye disease.

In this letter to the editor, investigators highlight the issues faced by patients with alopecia areata and the common barriers to JAK inhibitor access.

A systematic review suggests introducing denatured or baked egg under supervision could reduce the burden of strict allergen avoidance.

Norouzi reflects on significant advances in glomerular disease from Q1 and looks ahead to what the rest of 2025 may have to offer.

A major factor of type 2 diabetes mellitus, dyslipidemia can potentially be prevented by closely monitoring lipid profiles.

The 25-mg brensocatib group showed statistically significant changes in FEV1 decline as well as pulmonary exacerbations.

Parent company VivaVision plans to request a type C meeting with the US Food and Drug Administration.

These data point to the necessity of incorporating disease burden in patient interactions and decision making for those under the age of 18 years.

Prophylactic treatment with IV magnesium led to a lower risk of cisplatin-associated AKI in patients with cancer undergoing cisplatin chemotherapy.

Simple choices like improving diet and increasing exercise can influence a healthy individual’s risk of developing cardiovascular disease.

These phase 2a data on IMG-007, a nondepleting anti-OX40 monoclonal antibody, highlight its efficacy among those with alopecia areata.

In this analysis, investigators compared older and younger patients with psoriasis in terms of drug survival and other results of biologic medications.

Real-world data show omalizumab, alone or with OIT, is effective and well-tolerated for IgE-mediated food allergy, with high response rates in adults.

Findings suggest frequent consumption of non-skimmed milk may heighten the risk of developing MAFLD.

Researchers indicated an association between the index and 365-day mortality.